In this activity, three experts discuss how to incorporate immune checkpoint inhibitor therapy into the management of individuals classified as part of the “special population” of patients not generally included in clinical trials.
The goal of this activity is to educate clinicians on the use of immune checkpoint inhibitors in special populations.
This activity is intended for hematology and oncology specialists, emergency medicine specialists, pulmonologists, nurses, pharmacists, and other healthcare professionals who treat and manage special populations not generally included in clinical trials.
Learning Objectives:
- Have increased knowledge regarding the
- Emerging literature examining the use of immune checkpoint inhibitors (ICIs) in special populations, such as those with autoimmune disease
- Have greater competence related to
- Identifying when a patient with cancer from a special population may be considered for treatment with an ICI
- Recognizing factors that may affect the safety and efficacy of ICIs in special populations
Approximate Time to Complete: 30 minutes
Credit Available: February 25, 2021 - February 25, 2022
Developed through a partnership between SITC and Medscape.
 |
|
Additional Resources for Clinicans from SITC:
